A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

Ferrari, Anthony, Vincent-Salomon, Anne, Pivot, Xavier, Sertier, Anne-Sophie, Thomas, Emilie, Tonon, Laurie, Boyault, Sandrine, Mulugeta, Eskeatnaf +35 more·2016·Nature Communications
DOI 10.1038/ncomms12222

Cited by (156)

Items 101–156 of 156

  1. Generalizing Correspondence Analysis for Applications in Machine Learning
    Hsiang Hsu, Salman Salamatian, Flávio P. Calmon · 2021 · IEEE Transactions on Pattern Analysis and Machine Intelligence
  2. Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
    Anne-Sophie Sertier, Anthony Ferrari, Roxane M. Pommier, Isabelle Treilleux, Sandrine Boyault, Mojgan Devouassoux‐Shisheboran, Janice Kielbassa, Emilie Thomas, Laurie Tonon, Vincent Le Texier et al. · 2023 · Cancer Research Communications
  3. Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial
    Wen‐Jia Zuo, Lin Ma, Zhihong Wang, Xuchen Cao, Xin-jian Jia, Wen‐he Zhao, Mingliang Zhang, Hongwei Yang, Mao-shan Chen, Jing Wang et al. · 2025 · Cancer Letters
  4. Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers
    Eric J. Jaehnig, Aranzazu Fernández-Martínez, Tanmayi D. Vashist, Matthew Valle Holt, Laterrica C. Williams, Jonathan Thomas Lei, Chang In Moon, Beom-Jun Kim, Yongchao Dou, Haoquan Zhao et al. · 2025 · Cell Reports Medicine
  5. CDK4/6 Inhibitors in HER2-positive Metastatic Breast Cancer
    Hervé Bischoff, Thierry Petit · 2026 · Clinical Breast Cancer
  6. Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
    Ji‐Yeon Kim, Kyunghee Park, Seock‐Ah Im, Kyung Hae Jung, Joohyuk Sohn, Keun Seok Lee, Jee Hyun Kim, Yaewon Yang, Yeon Hee Park · 2020 · Breast Cancer Research and Treatment
  7. « HER2-faible », un nouveau concept dans la prise en charge des cancers du sein
    Élise Deluche, Anne Vincent‐Salomon · 2021 · Bulletin du Cancer
  8. Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)
    Rosalba Torrisi, Raffaella Palumbo, Rita De Sanctis, Patrizia Vici, Giulia Bianchi, Laura Cortesi, Vita Baldassara Leonardi, Rossana Gueli, Alessandra Fabi, Maria Rosaria Valerio et al. · 2021 · Breast Cancer Research and Treatment
  9. Breakage fusion bridge cycles drive high oncogene copy number, but not intratumoral genetic heterogeneity or rapid cancer genome change
    Siavash R. Dehkordi, Ivy Tsz-Lo Wong, Jing Ni, Jens Luebeck, Kaiyuan Zhu, Gino Prasad, Lena Krockenberger, Guanghui Xu, Biswanath Chowdhury, Utkrisht Rajkumar et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  10. The clinical value of radiomics models based on multi-parameter MRI features in evaluating the different expression status of HER2 in breast cancer
    Tingting Liu, Jialu Lin, Jiulou Zhang, Jianjuan Lou, Qigui Zou, Siqi Wang, Cong Wang, Yangqian Jiang · 2025 · Acta Radiologica
  11. Breast cancer genomic analyses reveal genes, mutations, and signaling networks
    Gowrang Kasaba Manjunath, Srihari Sharma, Disha Nashier, Shruthi Vasanthaiah, Spriha Jha, Saloni Bage, Tamoghna Mitra, Pankaj Goyal, Muniasamy Neerathilingam, Abhishek Kumar · 2024 · Functional & Integrative Genomics
  12. Epstein–Barr virus immediate-early protein Zta mediates the proliferation and migration of HER2-overexpressing cancer cells
    Hongling Zheng, Haitao Zhao, Wei Zhang, Yan Zhang, Yun Zhang, Bing Ye, Qingwei Guo · 2023 · Archives of Virology
  13. Insights into the pleiotropic roles of ZNF703 in cancer
    Shuang Wang, Rong Liu · 2023 · Heliyon
  14. Recognition of Specific PIP2-subtype Composition Triggers the Allosteric Control Mechanism for Selective Membrane Targeting of Cargo Loading and Release Functions of the Intracellular Sterol Transporter StarD4
    Hengyi Xie, Harel Weinstein · 2025 · Journal of Molecular Biology
  15. Apport et défis des Big Data en cancérologie
    Pierre Saintigny, Jean‐Philippe Foy, Anthony Ferrari, Philippe Alexandre Cassier, Alain Viari, Alain Puisieux · 2016 · Bulletin du Cancer
  16. Whole Genome Expression Analysis Identifies Multiple Targeted Integrative Effects of Polyphenol-Rich Propolis on HER-2-Positive Breast Cancer Cell Line
    Mehmet Fatih Seyhan, Özlem Timirci‐Kahraman, Allison Pınar Eronat, Eren Yilmaz, Ayşe Begüm Ceviz, Halil İbrahim Kısakesen, Tulin Kilicaslan Ozturk, Hülya Yılmaz, Oğuz Öztürk · 2024 · Records of Natural Products
  17. Engineering T Cells for Cancer: The Evolution and Future of CAR-Based Therapies
    Apsara Unni, S. Ragavendra · 2025 · Next Research
  18. Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review
    Marina Elena Cazzaniga, Luís Costa, Gilles Freyer, Joseph Gligorov, Henrik Lindman, Piotr Jan Wysocki, Rupert Bartsch · 2025 · Oncology and Therapy
  19. MAF1 is a predictive biomarker in HER2 positive breast cancer
    Stephanie Cabarcas‐Petroski, Gabriella Olshefsky, Laura Schramm · 2023 · PLoS ONE
  20. Distinct genetic landscape and a low response to doxorubicin in a luminal-A breast cancer cell line of Pakistani origin
    Muhammad Shakeel, Salman Khan, Anum Jabeen Mughal, Muhammad Irfan, Daniel C. Hoessli, Muhammad Iqbal Choudhary, Muhammad Aurongzeb, Ishtiaq Ahmad Khan · 2021 · Molecular Biology Reports
  21. Pharmacoproteogenomic approach identifies on-target kinase inhibitors for cancer drug repositioning
    Rei Noguchi, Julia Osaki, Takuya Ono, Yuki Adachi, Shuhei Iwata, Yuki Yoshimatsu, Kazuki Sasaki, Akira Kawai, Tadashi Kondo · 2024 · In Vitro Cellular & Developmental Biology - Animal
  22. Ketone drink enhances therapeutic efficacy in prostate cancer by targeting EZH2
    Chaehyun Yum, Richard A Schäfer, Rui Wang, Ting-You Wang, Xiaotong Jacinta Lu, Qi Liu, Yanan Ren, Qingshu Meng, Yong Yang, Xin Zhang et al. · 2025 · Oncogenesis
  23. Co-optimization of algorithm and sensor array for precise diagnosis of HER2-positive breast cancer and trastuzumab response prediction
    Tianyu Zeng, Zeying Li, Yanting Sun, Yincheng Liu, Jialin Xu, Xiang Huang, Yan Liang, Hai Shi, Shuai Wu, Genxi Li et al. · 2026 · Advanced Composites and Hybrid Materials
  24. Comprehensive genomic landscape of ERBB2 in Chinese GI tumors: mutation-centered landscapes and precision treatment opportunities
    Yinan Shi, Xiaoxuan Wang, Xiaotong Xi, Mengxiao Wang, J H Guo, Xing Zhang, Dongsheng Chen, Wenhui Yang · 2026 · Therapeutic Advances in Medical Oncology
  25. Glucose Transporter 4 and Interleukin 8 expression in hormone receptor negative/HER2 overexpressing breast carcinoma subtype: Correlation with biological behavior of the tumor cells and prognostic parameters
    Marwa A. Abd El-Azeem · 2021 · International Journal of Cancer and Biomedical Research
  26. Cellules tumorales circulantes : au cœur de la plasticité tumorale
    Alexia Lopresti, Claire Acquaviva, Daniel Birnbaum, Émilie Mamessier · 2017 · médecine/sciences
  27. Correspondence Analysis of Government Expenditure Patterns
    Hsiang Hsu, Flávio P. Calmon, José Cândido Silveira Santos Filho, Andre du Pin Calmon, Salman Salamatian · 2018 · arXiv (Cornell University)
  28. A new agent in the family of antibody–drug conjugates
    Xavier B. Pivot, Thierry Petit · 2019 · The Lancet Oncology
  29. Convergent mutations in tissue-specific regulatory regions reveal novel cancer drivers
    Nasa Sinnott-Armstrong, José Antonio Seoane, Richard C. Sallari, Jonathan K. Pritchard, Christina N. Curtis, Michael P. Snyder · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  30. Gemcitabine Resistance Elicits a Calcium Dependent Epigenetic Reprogramming in Pancreatic Cancer
    Ana P. Kutschat · 2021
  31. References
    Jacques Barbet, Adrien Foucquier, Yves Thomas · 2020
  32. Data from STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer
    Ana P. Kutschat, Feda H. Hamdan, Xin Wang, Alexander Q. Wixom, Zeynab Najafova, Christine Silvia Gibhardt, Waltraut Kopp, Jochen Gaedcke, Philipp Ströbel, Volker Ellenrieder et al. · 2023
  33. Data from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
    Anne-Sophie Sertier, Anthony Ferrari, Roxane M. Pommier, Isabelle Treilleux, Sandrine Boyault, Mojgan Devouassoux‐Shisheboran, Janice Kielbassa, Emilie Thomas, Laurie Tonon, Vincent Le Texier et al. · 2023
  34. Data from Dissecting the origin of heterogeneity in uterine and ovarian carcinosarcomas
    Anne-Sophie Sertier, Anthony Ferrari, Roxane M. Pommier, Isabelle Treilleux, Sandrine Boyault, Mojgan Devouassoux‐Shisheboran, Janice Kielbassa, Emilie Thomas, Laurie Tonon, Vincent Le Texier et al. · 2023
  35. Genomic Alterations Correlated to Trastuzumab Resistance and Clinical Outcomes in HER2+/HR- Breast Cancers of Patients Living in Northwestern China
    Gang Ma, Binliang Huo, Yanwei Shen, Xulong Zhu, Chong Cheng, Wensheng Li, Wei Cao, Jianhui Li · 2024 · Journal of Cancer
  36. Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review
    Катерина Сергеевна Гречухина, Daria Filonenko, Маргарита Витальевна Сухова, Lyudmila Zhukova · 2024 · Journal of Modern Oncology
  37. Pharmacogenomics: Personalized medicine and its impact on breast cancer
    Omar Obaid Alharbi · 2019 · International Journal of Health Sciences
  38. Liquid biopsy-based technologies: a promising tool for biomarker identification in her2-low breast cancer patients for improved therapeutic outcomes
    Aldo d'Alessandro, Anca Florentina Deaconu, S Mandolesi, Federico Pio Fabrizio, Massimo Lombardi, Giovanna Liguori, Giovanni Pepe, Nicola Marino, Aureliano Stingi, Alessandro d'Alessandro et al. · 2024 · Journal of Cancer Metastasis and Treatment
  39. Les lésions apocrines du sein
    Gaëtan Marie MacGrogan · 2025 · Annales de Pathologie
  40. Genomic and clinical‑pathological features of mucinous cystadenocarcinoma of the breast with HER2 amplification: A case report
    Liling Liu, Mingxian Li, Xinmin Qiu, Xirun Zheng, Guangjuan Zheng, Haifeng Yang · 2025 · Oncology Letters
  41. A network model for patient-derived drug response in breast cancer integrating multi-omics datasets
    Banabithi Bose, Barbara E. Stranger, Serdar Bozdag · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  42. Additional file 3 of Mutational landscape of inflammatory breast cancer
    François Bertucci, Lerebours, Florence, Ceccarelli, Michele, Arnaud Guillé, Syed, Najeeb, Pascal Finetti, José Adélaı̈de, Van Laere, Steven, Anthony Gonçalvès, Patrice Viens et al. · 2024 · Figshare
  43. Additional file 8 of Mutational landscape of inflammatory breast cancer
    François Bertucci, Lerebours, Florence, Michele Ceccarelli, Arnaud Guillé, Syed, Najeeb, Pascal Finetti, José Adélaı̈de, Van Laere, Steven, Anthony Gonçalvès, Patrice Viens et al. · 2024 · Figshare
  44. Additional file 7 of Mutational landscape of inflammatory breast cancer
    François Bertucci, Lerebours, Florence, Ceccarelli, Michele, Arnaud Guillé, Syed, Najeeb, Pascal Finetti, José Adélaı̈de, Van Laere, Steven, Anthony Gonçalvès, Patrice Viens et al. · 2024 · Figshare
  45. Additional file 1 of Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
    Noortje Verschoor, Marcel Smid, Jager, Agnes, Stefan Sleijfer, Saskia M. Wilting, Martens, John W. M. · 2023 · Figshare
  46. Additional file 1 of Mutational landscape of inflammatory breast cancer
    François Bertucci, Lerebours, Florence, Ceccarelli, Michele, Arnaud Guillé, Syed, Najeeb, Pascal Finetti, José Adélaı̈de, Van Laere, Steven, Anthony Gonçalvès, Patrice Viens et al. · 2024 · Figshare
  47. Additional file 5 of Mutational landscape of inflammatory breast cancer
    François Bertucci, Lerebours, Florence, Michele Ceccarelli, Arnaud Guillé, Syed, Najeeb, Pascal Finetti, José Adélaı̈de, Van Laere, Steven, Anthony Gonçalvès, Patrice Viens et al. · 2024 · Figshare
  48. Additional file 4 of Mutational landscape of inflammatory breast cancer
    François Bertucci, Lerebours, Florence, Michele Ceccarelli, Arnaud Guillé, Syed, Najeeb, Pascal Finetti, José Adélaı̈de, Van Laere, Steven, Anthony Gonçalvès, Patrice Viens et al. · 2024 · Figshare
  49. Additional file 6 of Mutational landscape of inflammatory breast cancer
    François Bertucci, Lerebours, Florence, Michele Ceccarelli, Arnaud Guillé, Syed, Najeeb, Pascal Finetti, José Adélaı̈de, Van Laere, Steven, Anthony Gonçalvès, Patrice Viens et al. · 2024 · Figshare
  50. Additional file 2 of Mutational landscape of inflammatory breast cancer
    François Bertucci, Lerebours, Florence, Ceccarelli, Michele, Arnaud Guillé, Syed, Najeeb, Pascal Finetti, José Adélaı̈de, Van Laere, Steven, Anthony Gonçalvès, Patrice Viens et al. · 2024 · Figshare
  51. Sustainable Biotechnology in Pharmaceuticals: Green Approaches and Innovations
    Priyanka Nayak, Surya Kanta Swain, Himansu Bhusan Samal · 2026 · Current Green Chemistry
  52. Molecular characterization of rare thoraco-abdominal tumours
    Noémie Leblay · 2018 · theses.fr (ABES)
  53. Caractérisation transcriptomique de l’hétérogénéité des lésions à potentiel malin et des carcinomes épidermoïdes HPV-négatifs de la cavité orale
    Jean‐Philippe Foy · 2018
  54. Representation learning in Computational Pathology : Application to the Prediction of Molecular Cancer Features
    Tristan Lazard · 2023
  55. HER2 Heterogeneity in Breast Cancer: Biological Basis, Clinical Implications, and Therapeutic Strategies
    Hanxiao Shi, Yiqian Feng, Tao Guo, Wenjun Shou, Yuandong Li · 2026 · Breast Cancer Targets and Therapy
  56. Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum
    Paolo Tarantino, Carmine Valenza, Elia Seguí, NU Lin, Aleix Prat, Giuseppe Curigliano, Adrienne Gropper Waks, Sara M. Tolaney · 2026 · Nature Reviews Clinical Oncology